Phagenesis appoints chairman and ceo

Will lead the development of treatments for stroke victims

Phagenesis, a UK leader in technology for the treatment of stroke patients, has appointed Henry Hyde-Thomson as chairman and Daniel Green as chief executive. They will lead the University of Manchester spin out in the development of a new class of treatments for stroke victims suffering from dysphagia, a condition that prevents or impairs the safe swallowing of food and drink.

Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can ‘awaken’ the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing. Apart from a severe reduction in quality of life, dysphagia often leads to the inhalation of liquids and the development of life-threatening pneumonia.

Green was formerly chief executive of Repregen, an Imperial College spinout. Before that, he was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort and MVM, in London, UK.

You may also like

Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Manufacturing

Accelerating self-administration and homecare with large-volume prefillable glass syringe

SCHOTT Pharma launches 5.5 ml syringe compatible with autoinjectors to enable comfortable home injections
Manufacturing

Aenova expands sterile fill & finish manufacturing at its Latina site

New line to boost biologics capacity and support a wide range of container formats
Research & Development

Certified biobased resins bring sustainable lab filtration to Cytiva’s customers

Certified materials enable labs to choose more sustainable options without changing workflows or compromising performance
Research & Development

Syngene International plans to add bioconjugation suite for end-to-end antibody-drug conjugates development

Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services
Research & Development

Cellarity unveils AI-driven framework for cell state-correcting drug discovery in the journal Science

Biotech innovator Cellarity publishes a breakthrough blueprint integrating multiomics and machine learning to accelerate discovery of complex disease therapies, alongside the release of three open-access single-cell datasets
Subscribe now